恶性血液病患者侵袭性真菌病初级预防的现状与未来

发布时间：2018-02-22 12:26

本文关键词： 恶性血液病侵袭性真菌病抗真菌初级预防　出处：《中国实验血液学杂志》2017年02期 　论文类型：期刊论文

【摘要】：侵袭性真菌病在恶性血液病化疗和造血干细胞移植患者中发病率及病死率很高。初级预防可有效减少侵袭性真菌病的发生,使患者对化疗和造血干细胞移植的耐受性更佳,治疗费用更低,预后更好。氟康唑、伊曲康唑、泊沙康唑、卡泊芬净、米卡芬净等抗真菌药物已被多个指南推荐用于初级预防。侵袭性真菌病风险预估、新型药物研发、药代动力学研究、综合预防措施的开展将使初级预防更加科学、合理、有效。本文就近年来恶性血液病患者侵袭性真菌病初级预防的进展作一综述
[Abstract]:Invasive fungal disease stem cell transplant recipients with high morbidity and mortality in malignant hematologic disease. Chemotherapy and hematopoietic primary prevention can effectively reduce the incidence of invasive fungal disease, so that patients on chemotherapy and hematopoietic stem cell transplantation are better tolerated, lower cost of treatment, the prognosis is better. Fluconazole, itraconazole, Bo Sha conazole, caspofungin, Mika Finn Jing and other antifungal drugs have been a guide recommended for primary prevention. Invasive fungal disease risk prediction, the research and development of new drugs, pharmacokinetics, comprehensive preventive measures will be carried out to make primary prevention more scientific, reasonable and effective. This article reviews the recent progress in patients with malignant blood disease primary prevention of invasive fungal disease

【作者单位】：中国人民解放军总医院血液科、解放军医学院;中国人民解放军总医院海南分院血液科;
【基金】：解放军总医院科技创新苗圃基金面上项目(13KMM01)
【分类号】：R733;R519

【相似文献】